Authors

• Louise A. Fearfield (ORCID: https://orcid.org/0000-0002-1122-4216)
• Vikash Dodhia (ORCID: https://orcid.org/0000-0001-5765-2577)
• Syed A. Hussain (ORCID: https://orcid.org/0000-0003-1552-511X)
• Maria Lapuente
• Robin L. Jones (ORCID: https://orcid.org/0000-0003-4173-3844)
• Jahangeer Malik
• Shona Crabb (ORCID: https://orcid.org/0000-0003-3651-2916)
• Harry Petruskin
• Davina Lau (ORCID: https://orcid.org/0009-0005-3744-868X)
• Nicola Jane Smith (ORCID: https://orcid.org/0009-0004-9940-1070)
• Naveed Sarwar
• Robert Stevenson
• Aisling Carr

Institutions

• St Bartholomew's Hospital (GB)
• University Hospitals Birmingham NHS Foundation Trust (GB)
• NHS Lothian (GB)
• Moorfields Eye Hospital NHS Foundation Trust (GB)
• University College London Hospitals NHS Foundation Trust (GB)
• Astellas Pharma (Japan) (JP)
• Imperial College Healthcare NHS Trust (GB)
• Chelsea and Westminster Hospital NHS Foundation Trust (GB)
• Edinburgh Cancer Research (GB)
• University Hospital Southampton NHS Foundation Trust (GB)
• Astellas Pharma (China) (CN)
• Astellas Pharma (United Kingdom) (GB)
• Mount Vernon Cancer Centre (GB)
• East and North Hertfordshire NHS Trust (GB)
• Chelsea and Westminster Hospital (GB)
• Moorfields Eye Hospital (GB)
• National Hospital for Neurology and Neurosurgery (GB)
• Astellas Pharma (Netherlands) (NL)
• Informa Healthcare (GB)
• University College London (GB)
• University of Glasgow (GB)
• University of Sheffield (GB)

Publication Details

Journal

The Oncologist

Published

2025-08-29

DOI

https://doi.org/10.1093/oncolo/oyaf220

Citations

1

Primary Topic

Bladder and Urothelial Cancer Treatments

Type

article

Field-Weighted Citation Impact

2.01